[On Demand]

PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline. PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection and therapy
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
CAM-H2, Her2 targeting single domain antibody linked to 131I
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Chief Business Officer